New combo therapy aims to shrink tumors before surgery
NCT ID NCT06884670
Summary
This study is testing if a new combination of immunotherapy drugs (tislelizumab and interleukin-2) plus standard chemotherapy works better than chemotherapy alone when given before surgery for locally advanced rectal cancer. The goal is to see if this approach shrinks tumors more effectively and leads to better outcomes. It will involve about 130 patients at multiple medical centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu province hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing BenQ Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Jiangsu University
RECRUITINGZhenjiang, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuzhou Central hospital
RECRUITINGXuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.